ThetaPal ThetaPal

Manufacturing / Biological Products, Except Diagnostic Substances

Beam Therapeutics Inc.

BEAM

$25.63

+$1.22 (+4.96%)

Price as of Oct 9, 2026 16:17 UTC

2.9 B

Market Cap (Mid Cap)

46%

IV Rank

82.2%

Implied Volatility

Nov 02

Next Earnings

Technical Signals as of Oct 7
Bearish
1 of 7

Trend

  • Above 20-day average $25.19
  • Above 50-day average $26.48
  • Above 200-day average $27.31 · -9.3%
  • Moving averages stacked Not aligned

Momentum

  • Golden cross (50/200) Down · 13d ago
  • Momentum cross (20/50) Down · 54d ago

Volume

  • Below-average volume 1.2x avg

Price & Trend

Daily candles with EMA 20, SMA 50. Drag to zoom.

Options Activity & Greeks

Implied volatility, flow, and dealer positioning from the options market.

Put/Call Ratio

0.03

Bullish skew

Implied Volatility

82.2%

0% percentile

IV vs Realized

Options rich

30d HV 50.8%

Options Heat Map

Delta-risk grid for BEAM options across strikes and expirations. Hover any cell for full Greeks.

Loading option chain data...

Insider Trades

0 buys 35 sells
Date Insider Title Type Shares Value Since Trade
Oct 01, 2026 Cavanagh Bethany J Sell 187 $4,565 +0.8%
Sep 24, 2026 Ciaramella Giuseppe Gift 123,407 $0 -0.2%
Jul 27, 2026 Simon Amy Sell 16,667 $429,037 -4.4%
Jun 30, 2026 Evans John M. Exercise 25,000 $25,750 +2288.3%
Jun 30, 2026 Evans John M. Sell 23,100 $791,482 -28.2%
Jun 30, 2026 Evans John M. Sell 1,900 $66,203 -29.4%
Jun 30, 2026 Evans John M. Exercise 25,000 $0 -28.3%
Jun 30, 2026 Simon Amy Sell 373 $12,954 -29.2%
Jun 29, 2026 Evans John M. Sell 13,421 $471,528 -30.0%
Jun 29, 2026 Evans John M. Exercise 18,663 $12,504 +3571.6%

Earnings History

Date Quarter EPS Est. EPS Actual Surprise Result
Aug 11, 2026 Q2 2026 -$1.13
Aug 03, 2026 Q2 2026 -$1.13
Jun 30, 2026 Q2 2026 -$1.13 -$1.18 -4.6% Miss
Mar 31, 2026 Q1 2026 -$1.12 -$0.91 +18.6% Beat
Dec 31, 2025 Q4 2025 -$1.01 -$0.10 +89.8% Beat
Sep 30, 2025 Q3 2025 -$1.06 -$1.10 -3.7% Miss

Track BEAM with ThetaPal

Get insider trade alerts, AI portfolio analysis, and options roll recommendations for BEAM and your entire portfolio.